Zevra Therapeutics Shows Long-Term Efficacy of MIPLYFFA in NPC with Real-World Data
Event summary
- Zevra Therapeutics presented two posters at the 2026 SSIEM Annual Symposium showcasing long-term real-world data on MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C (NPC).
- Data demonstrated durable disease stabilization over 4 years with minimal changes in disease severity scores.
- Real-world treatment experience spans up to 8 years, with 95.8% of participants receiving arimoclomol plus miglustat.
- No discontinuations due to treatment-related side effects were reported, though some participants experienced clinical deterioration after stopping arimoclomol.
The big picture
Zevra Therapeutics' presentation of long-term real-world data for MIPLYFFA® in NPC underscores the growing body of evidence supporting its efficacy and safety. This data is critical as the company seeks broader regulatory approvals and aims to solidify its position in the rare disease therapeutics market. The focus on long-term outcomes aligns with the industry trend toward demonstrating sustained benefits for chronic and progressive conditions.
What we're watching
- Regulatory Progress
- Whether Zevra Therapeutics can secure Marketing Authorization from the EMA for arimoclomol in NPC.
- Clinical Validation
- How the long-term real-world data will influence adoption and reimbursement decisions for MIPLYFFA.
- Market Expansion
- The pace at which Zevra can expand geographic access for MIPLYFFA beyond the U.S.